Kedudukan dalam Saham
#37880
BerGenBio ASA is a biopharmaceutical firm in the clinical development stage,... BerGenBio ASA is a biopharmaceutical firm in the clinical development stage, focused on developing therapies for drug-resistant, immune-evasive, and metastatic cancers, in addition to respiratory conditions. Its leading compound, Bemcentinib, is a bio-available small molecule AXL inhibitor currently in Phase II clinical trials for major cancer indications and COVID-19. The Phase II trial program specifically addresses non-small cell lung cancer, acute myeloid leukemia, myelodysplastic syndrome, and COVID-19. Moreover, the company is progressing tilvestamab, an anti-AXL antibody, through Phase Ib clinical trials. BerGenBio ASA also maintains a collaboration agreement with Merck & Co. for its clinical studies. The company was founded in 2007 and operates from its base in Bergen, Norway.
Harga Saham
$0.051239
Disegerakkan terakhir: 2025-11-24
Perubahan (1 hari)
-4.48%
Perubahan (1 tahun)
-54.57%
Perdagangan BerGenBio ASA (BGBIO)
Harga BGBIO dengan permodalan pasaran b
Modal pasaran bagi BerGenBio ASA(BGBIO)
Modal Pasaran: $1.38M
Sehingga August 2026, BerGenBio ASA mempunyai modal pasaran sebanyak $1.38M. Ini menjadikan BerGenBio ASA syarikat ke-37880th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran BerGenBio ASA dari 2017 hingga 2026
BGBIO berbanding dengan 5 teratas yang paling popular stocks
| Harga BGBIO |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.452T
|
+395,719,658.51%
|
|
|
|
|
$4.490T
|
+325,904,669.51%
|
|
|
|
|
$4.162T
|
+302,125,113.01%
|
|
|
|
|
$3.676T
|
+266,844,477.57%
|
|
|
|
|
$2.833T
|
+205,634,188.75%
|
